Proceedings - Clinical Pharmacology - Veterinary Healthcare
  • SEARCH:

ADVERTISEMENT

Proceedings - Clinical Pharmacology
Source: CVC IN BALTIMORE PROCEEDINGS

Drug dose adjustments for disease (Proceedings)

April 1, 2010

There is considerable evidence to support the adjustment of drug dosages in human patients with heart failure, hepatic failure, or renal insufficiency. In contrast, similar studies are lacking in dogs and cats. This presentation will discuss veterinary situations in which drug dose adjustments may be warranted.

Source: CVC IN BALTIMORE PROCEEDINGS

Practical tips for fluid and colloid therapy (Proceedings)

April 1, 2010

Hypovolemia vs. dehydration

Source: CVC IN BALTIMORE PROCEEDINGS

Antimicrobial dosing strategies: Applying PK/PD principles (Proceedings)

April 1, 2010

Concerns regarding bacterial resistance to antimicrobials are increasing the awareness of rational use in human and veterinary medicine. Successful antimicrobial therapy relies on administering sufficient doses so that pathogens at the site of infection are killed or sufficiently suppressed so that they can be eliminated by the host's immune system.

Source: CVC IN BALTIMORE PROCEEDINGS

Empirical antimicrobial therapy: making decisions without a culture (Proceedings)

April 1, 2010

The first step in empirical antimicrobial therapy is to first critically ask whether there is good evidence of a bacterial infection. Too often, antimicrobials are prescribed on a 'just in case' basis or because an owner resists additional diagnostics.

Source: CVC IN BALTIMORE PROCEEDINGS

NSAID's: Comparative toxicity and drug interactions (Proceedings)

April 1, 2010

With the availability of many over-the-counter NSAID's, and several newer, relatively cyclooxygenase-2 (COX-2) selective agents marketed for veterinary patients, there are many choices for controlling acute and chronic pain and inflammation. Because patients are often given NSAID's in the presence of concurrent disease and along with other drugs, the potential for NSAID-related organ toxicity and NSAID-associated drug interactions should always be considered.

Source: CVC IN BALTIMORE PROCEEDINGS

Drug compounding and issues (Proceedings)

April 1, 2010

Drug companies cannot supply labeled drug products to treat every condition in every species, and veterinarians often turn to extra-label drug use (ELDU) to fill these unmet therapeutic needs. A special form of ELDU is compounding medications.

Source: CVC IN BALTIMORE PROCEEDINGS

Interpreting drug company marketing (Proceedings)

April 1, 2010

Information about veterinary drugs, both new and old, is presented to practitioners on a daily basis. This information is vital to educated and rational use of drugs as clinical conditions change and new situations arise. However, like any competitive industry, veterinary pharmaceutical companies need to market their products in a manner that will influence consumers (the veterinarian) to use them.

Source: CVC IN BALTIMORE PROCEEDINGS

White feet, maybe treat? Testing for the MDR-1 gene in collie breeds (Proceedings)

April 1, 2010

Pharmacogenomics is an emerging field studying how genetic differences within a population can cause differences in pharmacology. Usually the genetic change will influence the pharmacokinetics of the drug, through altered drug absorption, distribution, metabolism, or excretion.

Source: CVC IN BALTIMORE PROCEEDINGS

Top ten drug interactions in dogs and cats (Proceedings)

April 1, 2010

In humans, the risk of adverse drug interactions multiplies as the number of administered drugs increases. Interactions can occur during IV drug administration, during oral absorption, at the target site, or during hepatic or renal elimination, and may lead to loss of efficacy or increased toxicity.

ADVERTISEMENT

Click here